Mattingly, T. Joseph II http://orcid.org/0000-0001-7786-5780
Slejko, Julia F. http://orcid.org/0000-0001-6900-9220
Onukwugha, Eberechukwu http://orcid.org/0000-0001-8547-1810
Perfetto, Eleanor M. http://orcid.org/0000-0001-8150-1058
Kottilil, Shyamasundaran http://orcid.org/0000-0001-7471-0812
Mullins, C. Daniel http://orcid.org/0000-0003-4322-2490
Funding for this research was provided by:
Patient-Centered Outcomes Research Institute (7709720-A)
Article History
First Online: 2 December 2019
Compliance with Ethical Standards
:
: The Stakeholder Advisory Board described in this manuscript was initiated with a research grant from the Patient-Centered Outcomes Research Institute (7709720-A).
: All input data for the decision analytical model are available within the article and the electronic supplementary material. The decision analytical model is available from the corresponding author on reasonable request.
: TJM reports consultant fees from G&W Labs, BMS, PhRMA, and NHC, all unrelated to this research. EO reports grants from Bayer Healthcare Pharmaceuticals, Inc. and from Pfizer, personal fees from Novo Nordisk, unrelated to this work. EMP is an employee of the National Health Council, which receives membership dues and sponsorship funding from a wide range of organizations. For the full list, please see ExternalRef removed. JFS reports grants from Novartis Pharmaceuticals, Takeda Pharmaceuticals, the PhRMA Foundation, and PhRMA unrelated to this work, as well as teaching honorarium from Pfizer. SK reports grants from Gilead Sciences, Merck, and Arbutus Pharma. CDM reports grants from Merck and consulting fees from Bayer, Boehringer-Ingelheim, Illumina, Janssen, Merck, Pfizer, Regeneron, and Sanofi.